Learning from host-defense peptides: Cationic, amphipathic peptoids with potent anticancer activity

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Huang, Wei ^a   Seo, Jiwon ^c   Willingham, Stephen B ^b   Czyzewski, Ann M ^d   Gonzalgo, Mark L ^a   Weissman, Irving L ^a,b   Barron, Annelise E ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PEPTOID; PEPTOID 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; STRUCTURE ACTIVITY RELATION; XENOTRANSPLANTATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PEPTIDES; PEPTOIDS; PROTEIN STABILITY; SOLID-PHASE SYNTHESIS TECHNIQUES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84896500814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090397     Document Type: Article

References (44)

1. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nature Reviews Immunology 8: 59-73.
2. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 10: 147-156.
3. Bhutia SK, Maiti TK (2008) Targeting tumors with peptides from natural sources. Trends Biotechnol 26: 210-217.
4. Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochimica Et Biophysica Acta-Biomembranes 1778: 357-375.
5. Leuschner C, Hansel W (2004) Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 10: 2299-2310. (Pubitemid 38855038)
6. Dennison SR, Whittaker M, Harris F, Phoenix DA (2006) Anticancer alphahelical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Current Protein & Peptide Science 7: 487-499. (Pubitemid 44883926)
7. Papo N, Shai Y (2005) Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62: 784-790. (Pubitemid 40655628)
8. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of Natural Products on Developing New Anti-Cancer Agents. Chem Rev 109: 3012-3043.
9. McPhee JB, Hancock REW (2005) Function and therapeutic potential of host defence peptides. Journal of Peptide Science 11: 677-687. (Pubitemid 41684254)
10. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395. (Pubitemid 34100944)
11. Melo MN, Ferre R, Castanho MARB (2009) OPINION Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nature Reviews Microbiology 7: 245-250.
12. Baker MA, Maloy WL, Zasloff M, Jacob LS (1993) Anticancer Efficacy of Magainin2 and Analog Peptides. Cancer Res 53: 3052-3057. (Pubitemid 23210311)
13. Park CB, Kim HS, Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244: 253-257. (Pubitemid 28419934)
14. Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC (2000) Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A 97: 8245-8250. (Pubitemid 30639657)
15. Czyzewski AM, Barron AE (2008) Protein and peptide biomimicry: Gold-mining inspiration from nature's ingenuity. Aiche Journal 54: 2-8.
16. Papo N, Shahar M, Eisenbach L, Shai Y (2003) A novel lytic peptide composed of DL-Amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 278: 21018-21023. (Pubitemid 36806412)
17. Papo N, Shai Y (2003) New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry (Mosc) 42: 9346-9354. (Pubitemid 36959242)
18. Papo N, Braunstein A, Eshhar Z, Shai Y (2004) Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: Membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64: 5779-5786. (Pubitemid 39095578)
19. Zuckermann RN, Kerr JM, Siani MA, Banville SC, Santi DV (1992) Identification of Highest-Affinity Ligands by Affinity Selection from Equimolar Peptide Mixtures Generated by Robotic Synthesis. Proc Natl Acad Sci U S A 89: 4505-4509.
20. Kirshenbaum K, Barron AE, Goldsmith RA, Armand P, Bradley EK, et al. (1998) Sequence-specific polypeptoids: A diverse family of heteropolymers with stable secondary structure. Proc Natl Acad Sci U S A 95: 4303-4308. (Pubitemid 28207907)
21. Wu CW, Sanborn TJ, Huang K, Zuckermann RN, Barron AE (2001) Peptoid oligomers with alpha-chiral, aromatic side chains: Sequence requirements for the formation of stable peptoid helices. J Am Chem Soc 123: 6778-6784. (Pubitemid 32884537)
22. Wu CW, Kirshenbaum K, Sanborn TJ, Patch JA, Huang K, et al. (2003) Structural and spectroscopic studies of peptoid oligomers with alpha-chiral aliphatic side chains. J Am Chem Soc 125: 13525-13530. (Pubitemid 37352134)
23. Patch JA, Barron AE (2003) Helical peptoid mimics of magainin-2 amide. J Am Chem Soc 125: 12092-12093. (Pubitemid 37238834)
24. Chongsiriwatana NP, Patch JA, Czyzewski AM, Dohm MT, Ivankin A, et al. (2008) Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci U S A 105: 2794-2799. (Pubitemid 351723623)
25. Czyzewski AM, Kapoor R, Chongsiriwatana NP, Dohm MT, Vakulenko S, et al. (In review) Antimicrobial peptoids with improved selectivity exhibit broadspectrum actvity against multi-drug resistant bacterial strains. Journal of antimicrobial agents and chemotherapy.
26. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci U S A 97: 13003-13008.
27. Burkoth TS, Fafarman AT, Charych DH, Connolly MD, Zuckermann RN (2003) Incorporation of unprotected heterocyclic side chains into peptoid oligomers via solid-phase submonomer synthesis. J Am Chem Soc 125: 8841-8845. (Pubitemid 36886222)
28. Fischer R, Kohler K, Fotin-Mleczek M, Brock R (2004) A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem 279: 12625-12635. (Pubitemid 38445834)
29. Gottler LM, Ramamoorthy A (2009) Structure, membrane orientation, mechanism, and function of pexiganan-A highly potent antimicrobial peptide designed from magainin. Biochimica Et Biophysica Acta-Biomembranes 1788: 1680-1686.
30. Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, et al. (2010) The Human Cathelicidin LL-37 Preferentially Promotes Apoptosis of Infected Airway Epithelium. Am J Respir Cell Mol Biol 43: 692-702.
31. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA (2004) Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 126: 9506-9507. (Pubitemid 39031015)
32. Makovitzki A, Fink A, Shai Y (2009) Suppression of Human Solid Tumor Growth in Mice by Intratumor and Systemic Inoculation of Histidine-Rich and pH-Dependent Host Defense-like Lytic Peptides. Cancer Res 69: 3458-3463.
33. Shai Y (2002) Mode of action of membrane active antimicrobial peptides. Biopolymers 66: 236-248. (Pubitemid 36098316)
34. Oren Z, Shai Y (1998) Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47: 451-463.
35. Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI (2010) Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells. Molecular Cancer Therapeutics 9: 2970-2981.
36. Buchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, et al. (2010) The Host Defense Peptide Cathelicidin Is Required for NK Cell-Mediated Suppression of Tumor Growth. J Immunol 184: 369-378.
37. Sok M, Sentjurc M, Schara M (1999) Membrane fluidity characteristics of human lung cancer. Cancer Lett 139: 215-220. (Pubitemid 29225123)
38. Rege K, Patel SJ, Megeed Z, Yarmush ML (2007) Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 67: 6368-6375. (Pubitemid 47037520)
39. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anticancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038. (Pubitemid 29439574)
40. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, et al. (2005) Tumorspecific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 102: 12962-12967. (Pubitemid 41279472)
41. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, et al. (2000) A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6: 1248-1252.
42. Boudreault PL, Arseneault M, Otis F, Voyer N (2008) Nanoscale tools to selectively destroy cancer cells. Chemical Communications: 2118-2120. (Pubitemid 351601263)
43. Tolley DA, Parmar MKB, Grigor KM, Lallemand G, Beynon LL, et al. (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup-Reply. J Urol 155: 1238-1238.
44. Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, et al. (2009) Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 119: 2830-2842.